公开(公告)号：US20150158873A1

公开(公告)日：2015-06-11

申请号：US14564352

申请日：2014-12-09

Applicant: AbbVie Inc.

Inventor： Andrew Bogdan ,  Warren M. Kati ,  Keith F. McDaniel ,  Chang H. Park ,  George S. Sheppard ,  Le Wang

IPC: C07D487/04 ,  C07D417/04 ,  C07D401/04 ,  C07D211/86 ,  C07D405/04

CPC classification number: A61K31/506 ,  A61K31/4412 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497 ,  C07D211/86 ,  C07D213/69 ,  C07D401/04 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D487/04

Abstract: The present invention provides for compounds of formula (I) wherein Y1, Y2, R1, R2, R3, A1, A2, A3, and A4, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Abstract translation: 本发明提供式（I）化合物，其中Y1，Y2，R1，R2，R3，A1，A2，A3和A4具有说明书中定义的任何值及其药学上可接受的盐，其是有用的 作为治疗疾病和病症的药剂，包括炎性疾病，癌症和艾滋病。 还提供了由一种或多种式（I）化合物组成的药物组合物。

公开(公告)号：US20150150884A1

公开(公告)日：2015-06-04

申请号：US14617448

申请日：2015-02-09

Applicant: AbbVie Inc.

Inventor： Dachun Liu ,  John Pratt ,  Le Wang ,  Lisa A. Hasvold ,  Andrew Bogdan

IPC: A61K31/55

CPC classification number: A61K31/55 ,  C07D471/12 ,  C07D471/16 ,  C07D471/22 ,  Y02A50/463

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Abstract translation: 本发明提供式（I）化合物，其中R1，R2，R6，Y1，Y2，A1，A2，A3和A4具有说明书中定义的任何值及其药学上可接受的盐，其可用作 治疗疾病和病症的药剂，包括炎性疾病，癌症和艾滋病。 还提供了包含一种或多种式（I）化合物的药物组合物。

公开(公告)号：US20250042894A1

公开(公告)日：2025-02-06

申请号：US18709204

申请日：2022-11-10

Applicant: Calico Life Sciences LLC ,  AbbVie Inc.

Inventor： Andrew Bogdan ,  Christos Economou ,  Jennifer M. Frost ,  Philip R. Kym ,  Spencer O. Scholz ,  Zhaoming Xiong

IPC: C07D417/14 ,  A61K31/433 ,  C07D417/04

Abstract: The present invention provides for compounds of Formula (I) wherein R1, has any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of non-small cell lung cancer.

公开(公告)号：US20240158368A1

公开(公告)日：2024-05-16

申请号：US18379351

申请日：2023-10-12

Applicant: AbbVie Inc.

Inventor： David A. Degoey ,  Michael R. Schrimpf ,  David J. Hardee ,  Jacob Ludwig ,  Eric R. Miller ,  Timothy R. Hodges ,  Alberto Munoz ,  Sarah J. Perlmutter ,  Huan-Qiu X. Li ,  Alvin Jang ,  Elizabeth L. Noey ,  Gregory A. Gfesser ,  Edgars Jecs ,  Robert G. Schmidt ,  Justin D. Dietrich ,  Xenia B. Searle ,  Boguslaw P. Nocek ,  Andrew Bogdan

IPC: C07D401/12 ,  A61P31/14

CPC classification number: C07D401/12 ,  A61P31/14

Abstract: Pyrrolidine main protease inhibitors are described that are effective as antiviral compounds.

公开(公告)号：US20230101559A1

公开(公告)日：2023-03-30

申请号：US17654547

申请日：2022-03-11

Applicant: AbbVie Inc.

Inventor： Andrew Bogdan ,  Steven Fidanze ,  Keith McDaniel ,  John Pratt ,  Le Wang

IPC: C07D401/12 ,  C07D213/64 ,  C07D401/04

Abstract: The present invention provides for compounds of formula (I) wherein R1, Y, X1, X2, R2, R3, R4, R5, R6, and m have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).

公开(公告)号：US20180334435A1

公开(公告)日：2018-11-22

申请号：US15952682

申请日：2018-04-13

Applicant: AbbVie Inc.

Inventor： Andrew Bogdan ,  Marlon D. Cowart ,  David A. DeGoey ,  Tammie K. Jinkerson ,  John R. Koenig ,  Michael E. Kort ,  Bo Liu ,  Mark A. Matulenko ,  Derek W. Nelson ,  Meena V. Patel ,  Hillary Peltier ,  Marc J. Scanio ,  Brian D. Wakefield

IPC: C07D215/48 ,  C07D487/04 ,  C07D405/12 ,  C07D487/08 ,  C07D401/12 ,  C07D471/04 ,  C07D417/14 ,  C07D405/14 ,  C07D409/14 ,  C07D401/14 ,  C07D409/12 ,  C07D417/12

CPC classification number: C07D215/48 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

公开(公告)号：US10035800B2

公开(公告)日：2018-07-31

申请号：US14774866

申请日：2014-03-12

Applicant: AbbVie Inc.

Inventor： Steven D. Fidanze ,  Dauchun Liu ,  Robert A. Mantei ,  Keith F. McDaniel ,  John Pratt ,  George S. Sheppard ,  Le Wang ,  Andrew Bogdan ,  James H. Holms ,  Justin D. Dietrich ,  Jasmina Marjanovic ,  Lisa A. Hasvold ,  Yujia Dai

IPC: A61K31/437 ,  C07D471/22 ,  C07D471/16

CPC classification number: C07D471/22 ,  A61P13/12 ,  A61P15/16 ,  A61P31/18 ,  A61P35/00 ,  C07D471/16

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y3, A1, A2, A3 and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

公开(公告)号：US20170226062A9

公开(公告)日：2017-08-10

申请号：US15239554

申请日：2016-08-17

Applicant: AbbVie Inc.

Inventor： Andrew Bogdan ,  Marlon D. Cowart ,  David A. DeGoey ,  Tammie K. Jinkerson ,  John R. Koenig ,  Michael E. Kort ,  Bo Liu ,  Mark A. Matulenko ,  Derek W. Nelson ,  Meena V. Patel ,  Hillary Peltier ,  Marc J. Scanio ,  Brian D. Wakefield

IPC: C07D215/48 ,  C07D409/14 ,  C07D487/08 ,  C07D471/04 ,  C07D487/04 ,  C07D405/14 ,  C07D417/14 ,  C07D401/12 ,  C07D401/14

CPC classification number: C07D215/48 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

公开(公告)号：US20160120841A1

公开(公告)日：2016-05-05

申请号：US14925649

申请日：2015-10-28

Applicant: AbbVie Inc.

Inventor： Philip R. Kym ,  Xueqing Wang ,  Xenia B. Searle ,  Bo Liu ,  Ming C. Yeung ,  Robert J. Altenbach ,  Eric Voight ,  Andrew Bogdan ,  John R. Koenig

IPC: A61K31/353 ,  A61K45/06 ,  C07D405/14 ,  A61K31/4433 ,  C07D491/052 ,  A61K31/435 ,  A61K31/4025 ,  A61K31/453 ,  C07D413/14 ,  A61K31/5377 ,  A61K31/397 ,  C07D491/107 ,  C07D407/12 ,  A61K31/436

CPC classification number: C07D407/12 ,  A61K31/00 ,  A61K31/353 ,  A61K31/397 ,  A61K31/4025 ,  A61K31/435 ,  A61K31/436 ,  A61K31/4433 ,  A61K31/453 ,  A61K31/5377 ,  A61K45/06 ,  C07D405/14 ,  C07D413/14 ,  C07D491/052 ,  C07D491/107 ,  A61K2300/00

Abstract: The invention provides for compounds of formula (I) wherein R1, X, Y, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, and R″ have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Abstract translation: 本发明提供式（I）化合物，其中R1，X，Y，R4，R5，R6，R7，R8，R9，R10，R11，R12，R13，R14，m和R“具有定义的任何值 在本说明书及其药学上可接受的盐中，其可用作治疗由CFTR介导和调节的疾病和病症的药剂，包括囊性纤维化，Siegren综合征，胰腺功能不全，慢性阻塞性肺病和慢性阻塞性气道疾病。 还提供了由一种或多种式（I）化合物组成的药物组合物。

公开(公告)号：US20140256710A1

公开(公告)日：2014-09-11

申请号：US14203651

申请日：2014-03-11

Applicant: AbbVie Inc.

Inventor： Dachun Liu ,  John Pratt ,  Le Wang ,  Lisa A. Hasvold ,  Andrew Bogdan

IPC: C07D471/16

CPC classification number: A61K31/55 ,  C07D471/12 ,  C07D471/16 ,  C07D471/22 ,  Y02A50/463

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Abstract translation: 本发明提供式（I）化合物，其中R1，R2，R6，Y1，Y2，A1，A2，A3和A4具有说明书中定义的任何值及其药学上可接受的盐，其可用作 治疗疾病和病症的药剂，包括炎性疾病，癌症和艾滋病。 还提供了包含一种或多种式（I）化合物的药物组合物。